X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
hepatitis c virus (8) 8
female (7) 7
gastroenterology & hepatology (7) 7
index medicus (7) 7
middle aged (7) 7
antiviral agents - therapeutic use (6) 6
ethnicity (6) 6
hepatitis c (6) 6
male (6) 6
adult (5) 5
genotype (5) 5
hepacivirus - genetics (5) 5
aged (4) 4
analysis (4) 4
chronic hepatitis c (4) 4
daa (4) 4
hcv (4) 4
hepatitis c - drug therapy (4) 4
antiviral agents (3) 3
belgium - epidemiology (3) 3
cohort studies (3) 3
gastroenterology (3) 3
gastroenterology and hepatology (3) 3
genetic aspects (3) 3
genotypes (3) 3
health aspects (3) 3
hepatitis (3) 3
hepatitis c, chronic - drug therapy (3) 3
incidence (3) 3
infections (3) 3
interferon (3) 3
patients (3) 3
plus ribavirin (3) 3
ribavirin (3) 3
treatment outcome (3) 3
antiviral treatment (2) 2
belgium (2) 2
body mass index (2) 2
cirrhosis (2) 2
efficacy (2) 2
epidemiology (2) 2
fibrosis (2) 2
genotype & phenotype (2) 2
genotype 4 (2) 2
hepacivirus - drug effects (2) 2
hepacivirus - physiology (2) 2
hepatology (2) 2
hiv (2) 2
insulin resistance (2) 2
insulin-resistance (2) 2
interferon-alpha (2) 2
ledipasvir (2) 2
liver (2) 2
liver cirrhosis (2) 2
liver disease (2) 2
medical services (2) 2
medicine (2) 2
metabolic factors (2) 2
peginterferon alpha-2a (2) 2
prevalence (2) 2
prospective studies (2) 2
rates (2) 2
research (2) 2
rna (2) 2
rna, viral - genetics (2) 2
treatment-naive patients (2) 2
virus diseases (2) 2
virus-infection (2) 2
abbreviated therapy (1) 1
abuse (1) 1
actigraphy (1) 1
activity cycles - drug effects (1) 1
adult; aged; anemia; antiviral agents; asthenia; cohort studies; dose-response relationship, drug; drug therapy, combination; female; hepacivirus; hepatitis c, chronic; host-pathogen interactions; humans; interferon-alpha; male; middle aged; neutropenia; outcome assessment; polyethylene glycols; proportional hazards models; rna, viral; recombinant proteins; ribavirin; withholding treatment; medicine (1) 1
adults (1) 1
adverse event (1) 1
affect - drug effects (1) 1
african continental ancestry group (1) 1
african continental ancestry group - statistics & numerical data (1) 1
aged, 80 and over (1) 1
alanine aminotransferase (1) 1
albendazole (1) 1
alpha-2a/ribavirin (1) 1
alveolar echinococcosis (1) 1
american (1) 1
analysis of variance (1) 1
anemia - chemically induced (1) 1
animals (1) 1
antiviral agents - administration & dosage (1) 1
antiviral agents - adverse effects (1) 1
antiviral agents - pharmacology (1) 1
antiviral drugs (1) 1
antiviral therapy (1) 1
arabs (1) 1
association (1) 1
asthenia - chemically induced (1) 1
biology and life sciences (1) 1
blood pressure (1) 1
blood-donors (1) 1
body mass (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutics and Clinical Risk Management, ISSN 1176-6336, 06/2016, Volume 12, pp. 861 - 872
Journal Article
Drug and Alcohol Dependence, ISSN 0376-8716, 2017, Volume 177, pp. 214 - 220
Journal Article
Therapeutics and clinical risk management, ISSN 1176-6336, 2016, Volume 12, Issue Issue 1, pp. 861 - 872
Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of care.... 
Antiviral agents | Treatment outcome | Analysis | Dosage and administration | Research | Hepatitis C | Drug therapy | Cell culture | Liver diseases | Clinical trials | Infections | Glycoproteins | RNA polymerase | FDA approval | Patients | Genotype & phenotype | Hepatitis | Hepatology | Gastroenterology | Interferon | Mutation | Drug dosages | sofosbuvir | HIV | DAA | Keywords : Ledipasvir | CHC
Journal Article
by Foster, Graham R and Coppola, Carmine and Derbala, Moutaz and Ferenci, Peter and Orlandini, Alessandra and Reddy, K. Rajender and Tallarico, Ludovico and Shiffman, Mitchell L and Ahlers, Silke and Bakalos, Georgios and Hassanein, Tarek and Basho, Jovan and Shabanaj, Gentian and Harxhi, Arjan and Debzi, Nabil and Afredj, Nawel and Guessab, Nawal and Mahindad, Nadir and Mahiou, Hassene and Aissaoui, Magda and Al Qameesh, Jihad and Al Ghandoor, Zuhal and Assene, Collins and Bastens, Boris and Brixko, Christian and Cool, Mike and De Galocsy, Chantal and Delwaide, Jean and George, Christophe and Laukens, Pierre and Lefebvre, Veronique and Mulkay, Jean-Pierre and Nevens, Frederik and Servais, Benoit and Van Vlierberghe, Hans and Horsmans, Yves and Henrion, Jean and Sprengers, Dirk and Michielsen, Peter and Bourgeois, Stefan and Lasser, Luc and Langlet, Philippe and Robaeys, Geert and Martinet, Jean-Paul and Warzee, Philippe and Hoste, Paul and Reynaert, Hendrik and Juriens, Irène and Decaestecker, Jochen and Van Der Meersch, Filip and Janssens, Filip and Ahmetagic, Sead and Verhaz, Antonija and Bevanda, Milenko and Calkic, Lejla and Ibrahimpasic, Nevzeta and Mesihovic, Rusmir and Mello, Carlos Eduardo and Ruiz, Fernando Jose and Junior, Elson Martins and Ferraz, Maria Lucia and Silva, Giovanni and Mendes, Claudio and Lyra, Andre and Silva, Mariliza Henrique and Gomide, Geisa and Fernandes, Julio Cesar and Pereira, Patricia and Correa, Maria Cassia and Teixeira, Rosangela and Yousry, Ayman and Hanno, Abdelfatah and Gabr, Mamdouh and Omar, Ashraf and Esmat, Gamal and Karatapanis, Stilianos and Nikolopoulou, Vassiliki and Giannoulis, Grigoris and Manolakopoulos, Spilios and Elefsiniotis, Ioannis and Drakoulis, Christos and Dimitroulopoulos, Dimitrios and Kanatakis, Stilianos and Ketikoglou, Ioannis and Mimidis, Konstantinos and Evgenidis, Nikolaos and Akriviades, Euaggelos and Vafiadi-Zoubouli, Irini and Tsianos, Epameinondas and Mela, Maria and Orfanou, Eleni and Mousoulis, Georgios and Karagiannis, Ioannis and Manesis, Emmanuel and Varga, Marta and Nemesánszky, Elemér and Fried, Katalin and Schuller, János and Szalay, Ferenc and Lengyel, Gabriella and ... and GUARD-C Study Grp and GUARD-C Study Group
PLoS ONE, ISSN 1932-6203, 03/2016, Volume 11, Issue 3, p. e0151703
Background Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains... 
MULTIDISCIPLINARY SCIENCES | Outcome Assessment (Health Care) - methods | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Host-Pathogen Interactions - drug effects | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Neutropenia - chemically induced | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Proportional Hazards Models | Anemia - chemically induced | Hepatitis C, Chronic - drug therapy | Withholding Treatment | Asthenia - chemically induced | Outcome Assessment (Health Care) - statistics & numerical data | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Cohort Studies | Influence | Care and treatment | Interferon | Research | Hepatitis C | Analysis | Laboratories | Medical services | Chronic infection | Viruses | Infections | Ribavirin | Impact analysis | Hepatitis | Ethics | Body mass index | Genotype & phenotype | Hepatology | Gastroenterology | Safety | Genotypes | Antiviral agents | Hematology | Enrollments | Lung diseases | Ribonucleic acid--RNA | Patients | Body mass | Body size | Clinical medicine | Hepatitis C virus | RNA | Ribonucleic acid
Journal Article
Liver International, ISSN 1478-3223, 08/2014, Volume 34, Issue 7, pp. e217 - e228
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 11/2019, Volume 69, Issue 10, pp. 1657 - 1664
Background. Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This... 
INFECTIOUS DISEASES | chronic kidney disease | GLECAPREVIR | EFFICACY | adverse event | RISK | MICROBIOLOGY | IMMUNOLOGY | VIROLOGICAL RESPONSE | RATES | HEPATOCELLULAR-CARCINOMA | PIBRENTASVIR | CIRRHOSIS | compensated cirrhosis | HCV | glecaprevir/pibrentasvir | Index Medicus | Major and Commentaries | pibrentasvir | glecaprevir
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 12/2016, Volume 29, Issue 3, pp. 302 - 308
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.